NCT03736967 2021-11-01
Efficacy and Safety of REGN3500 Monotherapy and Combination of REGN3500 Plus Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis
Regeneron Pharmaceuticals
Phase 2 Terminated
Regeneron Pharmaceuticals
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins